Alpha Synuclein N-terminal Antibody,StressMarq Biosciences Inc.,SMC-621D
Mouse Anti-Human Alpha Synuclein N-terminal Monoclonal IgG1
Host
Mouse
Reactivity
Human, Mouse, Rat
Application
WB , IHC
Conjugate
APC, ATTO 390, ATTO 488, ATTO 594, Biotin, FITC, HRP, PerCP, RPE, Unconjugated
Platform ID
BAB025808049

StressMarq Biosciences Inc.
Headquarters
118-1537 Hillside Avenue, Victoria, British Columbia, V8T 4Y2, CANADA
Contact
Tel: +1 250-294-9065
Fax: +1 250-294-9025
Email:
Specifications
Scientific Background
Alpha-synuclein is a presynaptic neuronal protein implicated in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and dementia with Lewy bodies. Among its structural domains, the N-terminal region plays a pivotal role in membrane binding, conformational dynamics, and aggregation behavior. Post-translational modifications, particularly C-terminal truncations, significantly influence alpha-synuclein’s aggregation propensity and neurotoxicity (1). C-terminally truncated alpha-synuclein species are highly enriched in pathological inclusions such as Lewy bodies and Lewy neurites. These truncated forms exhibit accelerated fibrillization and enhanced prion-like propagation in cellular and animal models of Parkinson’s disease, underscoring their pathogenic relevance (1). Importantly, such truncations can alter the structural conformation of alpha-synuclein, masking epitopes commonly targeted by antibodies, including those recognizing phosphorylated serine 129 (pSer129) . This epitope masking has critical implications for research and diagnostics. Antibodies specific to pSer129 may fail to detect C-terminally truncated alpha-synuclein, potentially underestimating the burden of pathogenic species in tissue samples. Therefore, careful selection of antibodies that target the N-terminal region is essential for accurate detection and quantification of disease-relevant alpha-synuclein conformers (3). Understanding the structural and functional roles of the alpha-synuclein N-terminus is vital for elucidating disease mechanisms and developing targeted therapeutic strategies in synucleinopathies.
Synonyms
Alpha Synuclein, α-Synuclein, SNCA, alphaSYN, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), isoform NACP140, PARK1, PARK 1, PARK4, PARK 4, Parkinson disease familial 1, Parkinson disease (autosomal dominant, Lewy body) 4, SYN, SYUA_HUMAN
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
Please provide the required information below so that we can quickly source your products.
